Cancer Cells Are Destroyed!
Good news about cancer came from the US-based pharmaceutical company Moderna. The US company announced that they managed to destroy cancerous cells thanks to mRNA technology, which is also used in corona vaccines, and that the risk of recurrence of the disease was reduced by 44 percent thanks to the vaccine.
US-based pharmaceutical company Moderna announced that it has succeeded in destroying cancerous cells by using mRNA technology, which is also used in coronavirus vaccines. In the statement made by the US-based company, it was stated that the vaccine showed effective results against melanoma, which causes skin cancer.
REDUCE THE RISK OF RE-VIEW by 44 PERCENT
It has been announced that if the drug called Keytruda, developed by Merck, is used together with the Moderna vaccine, the risk of recurrence or death in fatal skin cancer is reduced by 44 percent compared to the use of Keytruda alone.
MODERNA AND BIONTECH’S SHARES RISE
“This result is a statistically significant and clinically significant improvement,” the companies said in a statement. While the shares of Moderna rose after the data were shared, the shares of BioNTech, the company of Turkish scientists Özlem Türeci and Uğur Şahin, who conduct mRNA-based vaccine studies, entered an upward trend. While this research is the first to show how the use of drugs together with mRNA vaccine technology will affect immunity, he stated that this method has technical implications on other types of cancer.
RISK OF SIDE EFFECTS 14.4 PERCENT
“These research results will provide a new perspective in cancer treatment,” said Paul Burton, vice president of medical development at Moderna. Studying 157 skin cancer patients with stage three and four, the scientists compared conditions using Keytru alone with conditions using both the mRNA-based vaccine and Keytruda. In cases where both drugs are used, the rate of side effects was recorded as 14.4 percent, while the rate of side effects in the use of Keytruda alone was 10 percent.
HOW DOES VACCINE WORK?
According to the news in Sözcü newspaper, tumor samples and healthy tissue samples are taken from the patient for a personalized vaccine. Next, experts analyze the gene sequence, mutating proteins and other data to develop a personalized cancer vaccine. When this mixture is injected into the patient, the patient’s cells work like a production center, producing copies of it, and the immune system can detect and destroy the tumor. Moderna also stated that a personalized vaccine can be produced in 8 weeks.
RESEARCH NOT YET REVIEWED
However, some experts announced that only a small part of this research was shared with the public. Speaking to the British Financial Times newspaper, experts also pointed out that the results of this research have not yet been published in a peer-reviewed journal.